Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy and safety of Wilate in paediatric VWD patients under 6 years of age - results of a prospective multicentre clinical study including recovery information.

Haemophilia : the official journal of the World Federation of Hemophilia - 1 Nov 2013

Nowak-Göttl U, Krümpel A, Russo A, Jansen M

Abstract excerpt

Treatment with exogenous von Willebrand factor (VWF) is indicated in patients with von Willebrand disease (VWD) in whom treatment with 1-deamino-8-d-arginine vasopressin/desmopressin is contraindicated. Wilate is a new generation plasma-derived concentrate of native VWF and coagulation factor VIII (FVIII) (in a physiological 1:1 ratio) developed for the treatment of VWD. This is the first study to report safety,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Child, Preschool
Share to Coagulants

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Factor VIII

Share to Half-Life

Share to Hemorrhage

Share to Infant

Share to von Willebrand Diseases

Share to von Willebrand Factor

Source

Identifiers

PMID: 23919249
DOI: 10.1111/hae.12237

Genes

VWF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy and safety of Wilate in paediatric VWD patients under 6 years of age - results of a prospective multicentre clinical study including recovery information.PMID 23919249Read ↗

Von Willebrand factor (Vonvendi®): the first recombinant product licensed for the treatment of von Willebrand diseaseSemantic proximity Read ↗

Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial.Semantic proximity Read ↗

[Perioperative therapy of von Willebrand disease. Demonstration of pathophysiology, clinical problems and therapy options using two case reports].Semantic proximity Read ↗

Von Willebrand disease in children: diagnosis and management of a pediatric cohort in one single center in Argentina.Semantic proximity Read ↗

Safety, efficacy and pharmacokinetics of rVIII-SingleChain in children with severe hemophilia A: results of a multicenter clinical trial.Semantic proximity Read ↗

Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.Semantic proximity Read ↗

Optimal dosing for vascular anomalies pediatric patients with population pharmacokinetic model of sirolimusSemantic proximity Read ↗

On‐demand treatment of bleeds in haemophilia patients with inhibitors: strategies for securing and maintaining predictable efficacy with recombinant activated factor VIISemantic proximity Read ↗

Surgery with emicizumab prophylaxis for two pediatric patients with severe haemophilia A with inhibitorsSemantic proximity Read ↗

Defining the role of recombinant activated factor VII in pediatric cardiac surgery: Where should we go from here?*Semantic proximity Read ↗

Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpuraSemantic proximity Read ↗

Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: results of an international clinical investigation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.